Comments
Glenmark Pharmaceuticals has received final nod from the US health regulator for generic Triamcinolone acetonide cream used for reducing itching, redness and swelling on skin.
The company’s US subsidiary “Glenmark Pharmaceuticals Inc has been granted final approval by the United States Food and Drug Administration for Triamcinolone acetonide cream USP, 0.1 per cent,” Glenmark said in a BSE filing.
The product is generic version of Delcor Asset Corporation’s Kenalog cream in the same strength, it added.
According to IMS Health sales data for the 12-month period ended June 2016, the Kenalog cream, 0.1 per cent market (includes brand and all available therapeutic equivalents) achieved annual sales of approximately $43.6 million, Glenmark said.
The company’s current portfolio consists of 108 products authorised for distribution in the US marketplace and 61 abbreviated new drug applications (ANDA’s) pending approval with the USFDA, it added.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.